Ershov F I, Grigorian S S, Semenenko T A, Malinovskaia V V, Tarasenko O A, Agafonov V I, Prozorovskiĭ S V
Zh Mikrobiol Epidemiol Immunobiol. 1991 Oct(10):42-5.
In this work the results of using interferon (IFN), Dibasol and the combination of these preparations for the urgent prophylaxis of influenza and acute respiratory diseases (ARD) among the employees of the Gamaleia Research Institute of Epidemiology and Microbiology (USSR Acad. Med. Sci.) are summarized. Reaferon and Dibasol decrease ARD morbidity 2 times and leukocytic IFN decreases it 1.4 times, while the combined administration of Dibasol and IFN has proved to be ineffective. Reaferon is mainly a prophylactic remedy; it has been found to bring about almost no decrease in the number of patients at the peak of morbidity, while pronouncedly decreasing it in two weeks after the administration of the preparation. Dibasol has a curative effect, sharply interrupting the beginning rise of morbidity. Reaferon normalizes the characteristics of the IFN status, decreasing the amount of circulating IFN and enhancing the capacity of leukocytes for producing alpha-IFN and gamma-IFN. For the prophylaxis of respiratory infections the use of Reaferon is advisable 3-4 weeks prior to the beginning of the epidemic and then, when the first cases of infection are registered, the course of prophylaxis with Dibasol should be carried out.
本文总结了在(苏联医学科学院)加马列亚流行病学与微生物学研究所的员工中,使用干扰素(IFN)、地巴唑以及这两种制剂联合用于流感和急性呼吸道疾病(ARD)紧急预防的结果。重组干扰素和地巴唑可使ARD发病率降低2倍,白细胞干扰素可使其降低1.4倍,而地巴唑与干扰素联合使用已证明无效。重组干扰素主要是一种预防性药物;已发现它在发病高峰期几乎不会使患者数量减少,而在给药两周后会使其显著减少。地巴唑具有治疗作用,能急剧阻断发病率的初期上升。重组干扰素可使IFN状态特征正常化,减少循环中的IFN量,并增强白细胞产生α-IFN和γ-IFN的能力。为预防呼吸道感染,建议在疫情开始前3 - 4周使用重组干扰素,然后,当登记到首例感染病例时,应进行地巴唑预防疗程。